TRVN - Trevena Inc Stock Price, Fair Value and News

0.42USD+0.01 (+2.44%)Delayed

Market Summary

USD0.42+0.01

Delayed

2.44%

TRVN Stock Price

View Fullscreen

TRVN RSI Chart

TRVN Valuation

Market Cap

7.7M

Price/Earnings (Trailing)

-0.19

Price/Sales (Trailing)

2.46

EV/EBITDA

-0.08

Price/Free Cashflow

-0.23

TRVN Price/Sales (Trailing)

TRVN Profitability

Operating Margin

46.54%

EBT Margin

-1435.07%

Return on Equity

526.06%

Return on Assets

-99.2%

Free Cashflow Yield

-429.85%

TRVN Fundamentals

TRVN Revenue

Revenue (TTM)

3.1M

Rev. Growth (Qtr)

-94.04%

TRVN Earnings

Earnings (TTM)

-40.3M

Earnings Growth (Yr)

-136.42%

Earnings Growth (Qtr)

-108.32%

Breaking Down TRVN Revenue

Last 7 days

7.7%

Last 30 days

10.5%

Last 90 days

-32.3%

Trailing 12 Months

-33.6%

How does TRVN drawdown profile look like?

TRVN Financial Health

Current Ratio

4.66

Debt/Equity

-3.87

Debt/Cashflow

-1.11

TRVN Investor Care

Shares Dilution (1Y)

104.13%

Diluted EPS (TTM)

-3.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.0M	2.4M	2.8M	3.1M
2022	932.4K	1.3M	0	1.7M
2021	3.3M	3.5M	637.0K	567.0K
2020	4.7M	4.1M	3.6M	3.1M
2019	0	0	0	5.2M
2018	0	4.4M	5.5M	5.7M
2016	7.5M	7.5M	5.6M	3.8M
2015	1.6M	3.0M	4.4M	6.3M
2013	339.4K	271.3K	203.1K	135.0K
2012	0	0	0	407.6K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Trevena Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 14, 2023	drake patricia m.	sold (taxes)	-1,119	0.61	-1,835	svp, chief commercial officer
Dec 14, 2023	demitrack mark	acquired	143,350	0.61	235,000	svp, chief medical officer
Dec 14, 2023	shin barry	sold (taxes)	-2,205	0.61	-3,616	svp, cfo
Dec 14, 2023	yoder robert t	sold (taxes)	-1,176	0.61	-1,929	svp, chief business officer
Dec 14, 2023	bourdow carrie l.	acquired	286,700	0.61	470,000	president & ceo
Dec 14, 2023	yoder robert t	acquired	71,675	0.61	117,500	svp, chief business officer
Dec 14, 2023	shin barry	acquired	143,350	0.61	235,000	svp, cfo
Dec 14, 2023	bourdow carrie l.	sold (taxes)	-4,345	0.61	-7,123	president & ceo
Dec 14, 2023	demitrack mark	sold (taxes)	-2,191	0.61	-3,593	svp, chief medical officer
Dec 14, 2023	drake patricia m.	acquired	45,750	0.61	75,000	svp, chief commercial officer

Which funds bought or sold TRVN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	DecisionPoint Financial, LLC	unchanged	-	-186	219	-%
Apr 19, 2024	Financial Perspectives, Inc	sold off	-100	-17.00	-	-%
Apr 19, 2024	Financial Perspectives, Inc	new	-	11.00	11.00	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	104	635	-%
Mar 11, 2024	VANGUARD GROUP INC	added	2.67	9,751	52,248	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-20,000	-	-%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	unchanged	-	83.00	505	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	47,674	47,674	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-18.39	-	-	-%

Are Funds Buying or Selling TRVN?

Are funds buying TRVN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TRVN

No. of Funds

Unveiling Trevena Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	1,827,615	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.99%	784,831	SC 13G
Jul 08, 2022	blackrock inc.	1.7%	2,811,074	SC 13G
Feb 04, 2022	blackrock inc.	6.8%	11,139,459	SC 13G
Mar 11, 2021	new enterprise associates 12, limited partnership	-	0	SC 13D/A
Jan 03, 2020	sabby management, llc	12.%	0	SC 13G/A

Recent SEC filings of Trevena Inc

View All Filings

Date Filed	Form Type	Document
May 03, 2024	DEFR14A	DEFR14A
Apr 29, 2024	DEF 14A	DEF 14A
Apr 22, 2024	8-K	Current Report
Apr 19, 2024	PRE 14A	PRE 14A
Apr 09, 2024	8-K	Current Report
Apr 03, 2024	DEFA14A	DEFA14A
Apr 01, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Mar 21, 2024	DEFA14A	DEFA14A
Mar 21, 2024	8-K	Current Report

Peers (Alternatives to Trevena Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Trevena Inc News

Latest updates

Trevena Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4	2018Q3	2018Q2	2016Q4	2016Q3
Revenue	-100.0%	-	180,000	3,021,000	2,270,750	1,520,500	770,250	20,000	100,500	181,000	178,000	209,000	69,000	3,000,000	2,308,000	1,616,000	924,000	232,000	3,000,000	2,500,000	-	-
Cost Of Revenue	631.7%	1,280,500	175,000	88,000	127,000	227,000	216,000	207,000	334,000	199,000	258,000	163,000	-	-	-	-	-	-	-	-	-	-
Costs and Expenses	11.7%	10,064,500	9,007,000	9,217,000	10,125,000	9,347,000	14,813,000	16,480,000	14,032,000	14,041,000	14,252,000	10,167,000	12,083,000	8,390,000	6,258,000	5,823,000	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	8,390,000	6,258,000	5,823,000	6,501,000	8,184,000	7,258,000	11,095,000	35,835,000	29,627,000
S&GA Expenses	0.9%	4,611,000	4,572,000	5,138,000	6,089,000	5,725,000	10,306,000	11,014,000	9,761,000	10,438,000	10,545,000	7,368,000	8,227,000	4,089,000	3,300,000	3,632,000	3,640,000	4,073,000	3,908,000	5,926,000	-	-
R&D Expenses	-2.0%	4,173,000	4,260,000	3,991,000	3,909,000	3,395,000	4,291,000	5,259,000	3,937,000	3,404,000	3,449,000	2,636,000	3,674,000	4,301,000	2,958,000	2,191,000	2,861,000	2,748,000	3,350,000	5,128,000	-	-
EBITDA Margin	14.4%	-13.09	-15.29	-17.55	-21.09	-25.98	-34.23	-47.64	-78.34	-57.54	-8.28	-8.76	-9.31	-	-	-	-	-	-	-	-	-
Interest Expenses	788.6%	1,866,000	210,000	1,122,000	446,000	530,000	325,000	-	-	-	-	-	-	-	-	29,000	117,000	441,000	515,000	597,000	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-13,953,000	-13,771,000	-	-	-11,871,000	-5,251,000	-6,222,000	-5,725,000	-6,445,000	-7,976,000	-4,483,000	-8,559,000	-	-
EBT Margin	11.7%	-14.35	-16.25	-18.73	-22.11	-26.96	-34.55	-48.10	-79.09	-58.27	-8.41	-8.91	-9.47	-	-	-	-	-	-	-	-	-
Net Income	-108.3%	-16,519,500	-7,930,000	-8,012,000	-7,819,000	-6,987,500	-14,981,000	-16,389,000	-13,953,000	-13,771,000	-14,022,000	-9,842,000	-11,871,000	-5,551,000	-6,222,000	-5,725,000	-6,445,000	-7,976,000	-4,483,000	-9,304,000	-	-
Net Income Margin	-15.6%	-12.89	-11.15	-15.93	-22.23	-32.27	-45.55	-62.37	-91.01	-77.72	-11.95	-10.26	-9.57	-	-	-	-	-	-	-	-	-
Free Cashflow	32.7%	-6,006,000	-8,926,000	-7,250,000	-10,874,000	-10,664,000	-11,950,000	-18,257,000	-12,616,000	-10,913,000	-11,835,000	-14,203,000	-6,922,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-10.0%	41.00	45.00	39.00	38.00	49.00	51.00	65.00	64.00	80.00	92.00	112	118	128	123	66.00	39.00	47.00	57.00	65.00	72.00	67.00
Current Assets	-10.8%	35.00	39.00	33.00	31.00	41.00	43.00	56.00	54.00	71.00	82.00	103	110	119	114	57.00	30.00	37.00	47.00	55.00	62.00	62.00
Cash Equivalents	-4.1%	34.00	35.00	28.00	27.00	38.00	25.00	23.00	50.00	68.00	80.00	92.00	99.00	111	114	56.00	29.00	34.00	31.00	25.00	22.00	34.00
Inventory	-100.0%	-	1.00	1.00	1.00	1.00	1.00	3.00	3.00	2.00	1.00	1.00	-	-	-	-	-	-	-	-	-	-
Net PPE	-5.1%	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00
Liabilities	16.1%	48.00	42.00	29.00	28.00	33.00	29.00	29.00	15.00	15.00	14.00	22.00	20.00	24.00	11.00	11.00	10.00	17.00	22.00	23.00	26.00	25.00
Current Liabilities	22.7%	8.00	6.00	8.00	8.00	9.00	9.00	10.00	9.00	9.00	7.00	15.00	14.00	17.00	4.00	4.00	3.00	9.00	14.00	15.00	17.00	17.00
Long Term Debt	-100.0%	-	30.00	14.00	13.00	13.00	13.00	13.00	-	-	-	-	-	-	-	-	-	-	-	-	-	5.00
LT Debt, Current	-	-	-	-	-	-	0.00	-	-	-	-	-	-	-	-	-	-	5.00	8.00	11.00	14.00	13.00
LT Debt, Non Current	3.9%	31.00	30.00	14.00	13.00	13.00	13.00	13.00	-	-	-	-	-	-	-	-	-	-	-	-	-	5.00
Shareholder's Equity	-315.8%	-7.66	4.00	10.00	10.00	16.00	22.00	36.00	49.00	65.00	78.00	91.00	98.00	104	111	55.00	29.00	30.00	35.00	42.00	46.00	42.00
Retained Earnings	-2.9%	-588	-571	-563	-555	-547	-540	-525	-510	-494	-480	-466	-452	-442	-430	-425	-418	-413	-406	-398	-393	-388
Additional Paid-In Capital	0.9%	580	575	573	566	563	562	561	560	559	558	557	550	546	542	480	448	443	441	440	440	430
Shares Outstanding	17.4%	17.00	15.00	14.00	9.00	8.00	7.00	7.00	7.00	7.00	7.00	7.00	6.00	6.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	276	-	-	-	276	-	-	-	189	-	-	-	94.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	32.9%	-5,985	-8,926	-7,250	-10,874	-10,664	-10,606	-11,950	-18,257	-12,616	-11,123	-12,045	-14,413	-7,132	-2,723	-5,321	-6,218	-6,805	-6,161	-3,018	-7,683	-5,700
Share Based Compensation	6.4%	733	689	702	806	749	764	1,008	1,155	1,136	978	1,182	1,111	840	787	766	891	917	768	793	754	848
Cashflow From Investing	-Infinity%	-21.00	-	-	-	18,000	11,994	-	-	1,164	-390	-374	-416	-27.00	-	-	3,500	11,998	14,768	9,857	-11,040	17,425
Cashflow From Financing	-74.5%	4,029	15,781	6,503	-2.00	7,956	1,100	14,451	-2.00	-271	-2.00	5,277	2,730	3,880	60,610	32,026	-1,496	-2,142	-3,176	-3,273	6,094	-3,170

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TRVN Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 3,125	$ (418)
Operating expenses:
Cost of goods sold	1,670	3,018
Selling, general and administrative	20,410	34,728
Research and development	16,333	18,211
Total operating expenses	38,413	55,957
Loss from operations	(35,288)	(56,375)
Other income (expense):
Change in fair value of warrant liability	2,126	11,180
Other expense, net	(4,522)	(7,681)
Interest income	1,398	451
Interest expense	(3,644)	(1,256)
(Loss) gain on foreign currency exchange	(41)	11
Foreign income tax expense	(318)
Total other income (expense), net	(5,001)	2,705
Net Loss	(40,289)	(53,670)
Other comprehensive loss
Unrealized gain on marketable securities		1
Comprehensive loss	$ (40,289)	$ (53,669)
Per share information:
Net loss per share of common stock, basic (in dollars per share)	$ (3.16)	$ (7.59)
Net loss per share of common stock, diluted (in dollars per share)	$ (3.16)	$ (7.59)
Weighted average common shares outstanding, basic (in shares)	12,735,010	7,072,362
Weighted average common shares outstanding, diluted (in shares)	12,735,010	7,072,362
Product revenue
Revenue:
Total revenue	$ (54)	$ (438)
License and royalty revenues
Revenue:
Total revenue	$ 3,179	$ 20

TRVN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 32,975	$ 38,320
Inventories		906
Prepaid expenses and other current assets	2,230	1,782
Total current assets	35,205	41,008
Restricted cash	540	1,960
Property and equipment, net	1,195	1,488
Right-of-use lease assets	3,665	4,224
Total assets	40,605	48,680
Current liabilities:
Accounts payable, net	2,303	2,372
Accrued expenses and other current liabilities	4,239	5,461
Lease liabilities	1,012	899
Total current liabilities	7,554	8,732
Loans payable, net	30,809	13,430
Leases, net of current portion	4,424	5,436
Warrant liability	5,475	5,483
Total liabilities	48,262	33,081
Stockholders' (deficit) equity:
Preferred stock-$0.001 par value; 5,000,000 shares authorized, none issued or outstanding at December 31, 2023 and 2022
Common stock-$0.001 par value; 200,000,000 shares authorized at December 31, 2023 and 2022; 17,289,104 and 7,744,692 shares issued and outstanding at December 31, 2023 and 2022, respectively	17	8
Additional paid-in capital	580,387	563,362
Accumulated deficit	(588,061)	(547,772)
Accumulated other comprehensive income		1
Total stockholders' (deficit) equity	(7,657)	15,599
Total liabilities and stockholders' equity	$ 40,605	$ 48,680

About Trevena Inc

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

CEO	Ms. Carrie L. Bourdow
WEBSITE	trevena.com
INDUSTRY	Biotechnology
EMPLOYEES	35

Trevena Inc Frequently Asked Questions

What is the ticker symbol for Trevena Inc? What does TRVN stand for in stocks?

TRVN is the stock ticker symbol of Trevena Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Trevena Inc (TRVN)?

As of Fri May 03 2024, market cap of Trevena Inc is 7.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TRVN stock?

You can check TRVN's fair value in chart for subscribers.

What is the fair value of TRVN stock?

You can check TRVN's fair value in chart for subscribers. The fair value of Trevena Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Trevena Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TRVN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Trevena Inc a good stock to buy?

The fair value guage provides a quick view whether TRVN is over valued or under valued. Whether Trevena Inc is cheap or expensive depends on the assumptions which impact Trevena Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TRVN.

What is Trevena Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, TRVN's PE ratio (Price to Earnings) is -0.19 and Price to Sales (PS) ratio is 2.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TRVN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Trevena Inc's stock?

In the past 10 years, Trevena Inc has provided -0.219 (multiply by 100 for percentage) rate of return.